- Associated Press - Wednesday, March 13, 2013

LONDON (AP) - After the best-selling Irish novelist Josephine Hart died from ovarian cancer in 2011, her husband was so devastated he often went to her grave to have breakfast.

And even now, Lord Maurice Saatchi describes his wife’s cancer treatment as “medieval.” A member of Parliament, he’s proposing a bill that would allow doctors to use experimental therapies even if there is no proof they work.

Hart and Saatchi were an oft-photographed celebrity couple in Britain more than a decade ago. She produced plays in London’s West End and hosted poetry readings featuring actors including Ralph Fiennes and Roger Moore. Her 1991 novel “Damage” was turned into a film starring Jeremy Irons and Juliette Binoche.

Saatchi, an advertising executive who sits in the House of Lords, acknowledges his bill was driven by grief at his wife’s death.

After a diagnosis in 2009 that her cancer was too advanced for surgery, Hart got chemotherapy and radiation, which Saatchi calls “degrading and ineffective.”

Though ovarian cancer is one of the hardest to catch and treat early, Saatchi says Britain’s current law is a serious barrier to new treatments. Theoretically doctors can be prosecuted if they try something that deviates from standard practice.

His bill is aimed at encouraging new therapies by allowing doctors to try them, including those lacking evidence of effectiveness. The decision would have to be made by several medical experts in different fields and doctors would need to tell their supervisors in advance as well as inform the patient of any opposing medical opinions.

While bills initiated by individual politicians rarely make it into law, Saatchi’s proposal has raised a broader issue about British health care: Survival rates for most cancers are worse than in other European countries including France, Germany and the United States. A report released this month said Britain ranked 16th out of 19 Western countries for ovarian cancer death rates.

Access to drugs is so poor the government started a 200 million pound (US$302 million) emergency fund in 2010 to try to get patients quicker treatment; the U.K. spends about half what France spends on cancer drugs.

According to the Organization for Economic Co-operation and Development, the five-year survival rate for breast cancer in the U.S. is 89 percent. In the U.K., it is 81 percent.

After the cancer drug Avastin was approved for use in the U.S., it took nearly another year for it to become available in Britain. For Tykerb, the delay was more than two years. Avastin is used to treat numerous cancers including those of the kidney, colon, and lung while Tykerb is used to treat breast cancer in combination with other drugs.

In a debate on Saatchi’s bill in the House of Lords in January, Lord Frederick Howe, a government health minister, lamented the contrast between Britain’s role as a world leader in health research and its lagging approval of new treatments for patients.

“It still takes an estimated average of 17 years for only 14 percent of new scientific discoveries to enter day-to-day clinical practice,” he said. “This is not acceptable.”

Several other members voiced support for Saatchi, citing other problems that have slowed medical advances, including bureaucracy and slashed budgets.

Some experts suggest that if Saatchi’s bill doesn’t make it into law in its current form, its key planks might be rolled into a government-sponsored bill, making it much likelier to succeed. Saatchi has even been advised by the U.K.’s top medical officer.”We’re very sympathetic to the points that Lord Saatchi has raised,” said Daniel Poulter, a minister in the Department of Health, during a televised discussion with Saatchi. “We’d certainly like to engage further.”

Story Continues →